Interview: John Markels – Managing Director, MSD Mexico
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
Address: Avenida San Jeronimo No.369, Tizapan San Angel, Mexico D.F.
,Mexico
Tel: +52 55 5481 9600
Web: http://www.corporativo.msd.com.mx/
MSD in Mexico is the local subsidiary of Merck & Co., Inc., a leading research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of innovative health care products. As the leading research-based pharmaceutical company in Mexico, MSD is committed to maintaining and improving the quality of human life above all else.
MSD Mexico participates in the preservation and extension of human life, creating a culture that promotes the commitment and passion in everything that is done. MSD Mexico offers value-added drugs and dominates all therapeutic classes in which it competes, most notably: cardiovascular, diabetes, neuroscience, osteoporosis, oncology and hepatitis C.
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture,…
Some 16 percent of Mexico’s population is battling diabetes—a number that represents one in five of the nation’s populace without including the vast numbers of undiagnosed Mexicans living with the…
See our Cookie Privacy Policy Here
